Developments in the inhibition of gastric acid secretion. - Wikidata - wikimedia - TriplyDB

Developments in the inhibition of gastric acid secretion.

Developments in the inhibition of gastric acid secretion.

http://www.wikidata.org/entity/Q36230670

about

The Indications, Applications, and Risks of Proton Pump Inhibitors Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438).A fibrin gel loaded with chitosan nanoparticles for local delivery of rhEGF: preparation and in vitro release studies.A Quantitative Structure-Activity Relationship and Molecular Modeling Study on a Series of Heteroaryl- and Heterocyclyl-Substituted Imidazo[1,2-a]Pyridine Derivatives Acting as Acid Pump Antagonists.Effect of perioperative proton pump inhibitors on the incidence of pharyngocutaneous fistula after total laryngectomy: a prospective randomized controlled trial.Inhibition of H+/K+ ATPase in the gastroprotective effect of Baccharis illinita DC.Docking studies of novel pyrazinopyridoindoles class of antihistamines with the homology modelled H(1)-receptor.Molecular modeling and QSAR studies of a set of indole and benzimidazole derivatives as H₄ receptor antagonists.Radiographic Localization Study of a Novel Potassium-Competitive Acid Blocker, Vonoprazan, in the Rat Gastric Mucosa.A Quantitative Structure-Activity Relationship and Molecular Modeling Study on a Series of Biaryl Imidazole Derivatives Acting as H+/K+-ATPase Inhibitors

P2860

Q36091187-36CFEAFB-645D-4FDA-979F-A0DBB211A0FF Q38861693-1F9D4A59-B561-49A3-BD93-795963248407 Q42812501-0371DD4E-B854-4D36-BD79-5F663FC27962 Q42971471-7D1DBEE5-3C76-4FCE-9CE1-2E3F16F345EA Q45908490-3D007368-D24E-4405-B628-7AE2E4305519 Q46471339-BF998FAE-0D6C-4143-B664-3577F0527371 Q48590212-A3E9C220-F64C-478A-9A4D-4849F0F07419 Q51682200-00EC36A6-55B2-42D0-A410-BA6E6D44E9CA Q52881408-32719154-EF6C-45CF-A19C-3E9156F86238 Q58920151-653FA0EA-A532-4B14-ACD7-93E8B7727792

P2860

Developments in the inhibition of gastric acid secretion.

http://www.wikidata.org/entity/Q36230670

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Developments in the inhibition of gastric acid secretion.

@ast

Developments in the inhibition of gastric acid secretion.

@en

type

label

Developments in the inhibition of gastric acid secretion.

@ast

Developments in the inhibition of gastric acid secretion.

@en

prefLabel

Developments in the inhibition of gastric acid secretion.

@ast

Developments in the inhibition of gastric acid secretion.

@en

P1433

Q36230670-D06296F6-D400-4C3C-A073-F05B07F9D648

P1476

Q36230670-413B5786-AF5E-4406-B839-DE7E82F0E597

P2093

Q36230670-87D3E27F-D1C0-4B8E-B9EB-763E6A4D74AD

Q36230670-92CB1948-51A5-4B88-ADD9-B48DAE9B0172

P2860

Q36230670-0B09A036-1631-4E87-B488-08216C8C0FD6

Q36230670-0ECFC9FC-BA81-4A65-846D-21AB68B7DF5B

Q36230670-1B22C4F3-7124-4C07-AEBB-A222C27E1FCB

Q36230670-1F40519B-D403-4FA5-85B9-334F80EBAF41

Q36230670-40D615D1-585D-42F1-8B35-7E6E398182FB

Q36230670-4145B108-1CF9-4FF2-B090-7EC25CE4CE4E

Q36230670-47D0750B-526A-4404-AF7D-23CF3CA5D8B4

Q36230670-5CBC8BFA-5861-43AE-9D8F-428FF53CCB77

Q36230670-5E4C8F35-C8E7-4C6B-BA9A-1BDA37B3E872

Q36230670-63DC8880-64A6-41E2-B4B7-B955B504C426

P304

Q36230670-2B9EBECD-BA84-47B8-B17D-A479BEDE7730

P31

Q36230670-2B669B33-FFA3-4914-8EAD-8ADFA410D40E

P356

Q36230670-0B28A049-5477-470C-9B07-B7736644EF8D

P433

Q36230670-5AE70C14-C6C3-4B02-933E-10B92E7A63DF

P478

Q36230670-E1AE3BE2-9028-4179-871F-DF05A0A39BAB

P577

Q36230670-49531222-D484-4817-AB17-7C10C02A16D5

P5875

Q36230670-2FD3194F-D80A-4576-9D62-4468CF256D8D

P698

Q36230670-14B1ED6E-3DCB-425E-A5CA-80028AF4E07F

P356

J.1365-2362.2005.01543.X

P1433

European Journal of Clinical Investigation

P1476

Developments in the inhibition of gastric acid secretion.

@en

P2093

Caca K

http://www.w3.org/2001/XMLSchema#string

Mössner J

http://www.w3.org/2001/XMLSchema#string

P2860

Are proton pump inhibitors the first choice for acute treatment of gastric ulcers? A meta analysis of randomized clinical trials

Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding

Meta-analysis: comparing the efficacy of proton pump inhibitors in short-term use.

Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers.

Short-term treatment of gastroesophageal reflux disease.

Direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer disease.

Reversible inhibitors of the gastric (H+/K+)-ATPase as both potential therapeutic agents and probes of pump function.

Regulation of gastric function by endogenous gastrin releasing peptide in humans: studies with a specific gastrin releasing peptide receptor antagonist.

Review article: new pharmacological agents for the treatment of gastro-oesophageal reflux disease.

Double-blind clinical comparison between a gastrin-receptor antagonist, proglumide, and a histamine H2-blocker, cimetidine.

P304

469-475

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2362.2005.01543.X

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

35

http://www.w3.org/2001/XMLSchema#string

P577

2005-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7658286

http://www.w3.org/2001/XMLSchema#string

P698

16101666

http://www.w3.org/2001/XMLSchema#string